- Windtree Therapeutics ( NASDAQ: WINT ) said on Tuesday the United States Patent and Trademark Office (USPTO) had issued a new patent for istaroxime administration, an investigational drug candidate in early cardiogenic shock and acute heart failure.
- The company said Phase 2 studies in acute heart failure have showed significant improvements in cardiac function as well as increasing blood pressure and preserving or increasing renal function.
- ( WINT ) has risen ~5% before the bell.
For further details see:
Windtree receives US patent for istaroxime to treat acute heart failure